NASDAQ · VSTM
Healthcare · Biotechnology
$8.00
Down-$0.25 (-3.12%)
Updated Oct 6, 2026, 9:32 PM
SID Score
5.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · VSTM
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
VSTM closed at $8.00 after 20 trading sessions, down 0.99% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $7.74 | $8.10 | $7.52 | $8.00 | 2.22M |
| Oct 2, 2026 | $7.95 | $8.015 | $7.52 | $7.70 | 4.07M |
| Oct 1, 2026 | $8.00 | $8.175 | $7.74 | $7.90 | 1.76M |
| Sep 30, 2026 | $7.98 | $8.40 | $7.92 | $8.05 | 1.57M |
| Sep 29, 2026 | $7.78 | $8.12 | $7.56 | $7.92 | 2.68M |
| Sep 28, 2026 | $7.59 | $7.78 | $7.39 | $7.77 | 1.26M |
| Sep 25, 2026 | $7.86 | $7.89 | $7.67 | $7.74 | 1.06M |
| Sep 24, 2026 | $8.10 | $8.195 | $7.71 | $7.80 | 1.84M |
| Sep 23, 2026 | $8.37 | $8.40 | $7.85 | $8.18 | 1.94M |
| Sep 22, 2026 | $8.04 | $8.645 | $8.00 | $8.37 | 3.06M |
| Sep 21, 2026 | $7.54 | $8.04 | $7.50 | $7.99 | 2.8M |
| Sep 18, 2026 | $7.58 | $7.84 | $7.40 | $7.44 | 4.5M |
| Sep 17, 2026 | $7.58 | $7.91 | $7.535 | $7.55 | 1.73M |
| Sep 16, 2026 | $7.35 | $7.41 | $7.195 | $7.32 | 1.45M |
| Sep 15, 2026 | $7.48 | $7.52 | $7.245 | $7.34 | 2.84M |
| Sep 14, 2026 | $7.36 | $7.62 | $7.25 | $7.51 | 1.51M |
| Sep 11, 2026 | $7.70 | $7.788 | $7.315 | $7.32 | 1.91M |
| Sep 10, 2026 | $7.91 | $7.91 | $7.45 | $7.62 | 2.67M |
| Sep 9, 2026 | $8.01 | $8.38 | $7.80 | $7.94 | 2.4M |
| Sep 8, 2026 | $8.20 | $8.54 | $7.89 | $8.08 | 4.37M |
The latest Smart Investors Daily articles mentioning VSTM.
Company
Market Activity
Research & News
VSTM research
Company profile and research snapshot.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 5, 2026 | HC Wainwright & Co. | Buy | — |
| Oct 5, 2026 | BTIG | Buy | — |
| Sep 17, 2026 | Wolfe Research | Outperform | — |
| Sep 11, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 11, 2026 | BTIG | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 28, 2026
BOSTON, September 28, 2026--Long-term RAMP 201 results published in Gynecologic Oncology reinforce durable clinical benefit and manageable safety profile in recurrent LGSOC.
Yahoo · Sep 24, 2026
BOSTON, September 24, 2026--Verastem to present late-breaking oral presentation of RAMP 201 LGSOC molecular profiling and tumor biomarker analysis at IGCS 2026
Yahoo · Sep 22, 2026
Verastem (NASDAQ:VSTM) executives outlined the company’s commercial and clinical priorities at an H.C. Wainwright event, highlighting the launch of its AVMAPKI FAKZYNJA CO-PACK for KRAS-mutated low-grade serous ovarian cancer and the advancement of its KRAS G12D inhibitor, VS-7375, across pancreatic
Benzinga · Sep 17, 2026
Wolfe Research analyst Kalpit Patel initiates coverage on Verastem (NASDAQ:VSTM) with a Outperform rating.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning VSTM.
